Label changes for sleep meds with zolpidem obtain FDA nod

05/14/2013 | Reuters

Label changes, including lower doses for sleep treatments with zolpidem, a drug that affects the mental alertness of patients even a day after its intake, were approved by the FDA. Driving and other activities that require complete mental alertness the following day should be avoided by patients who receive zolpidem extended-release medications, the agency said. The approval covered label changes for Sanofi's Ambien and Ambien CR, as well as Meda's Edluar.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA